4886 — ASKA Pharmaceutical Holdings Co Share Price
0.000.00%
Last trade - 00:00- ¥63bn
- ¥52bn
- ¥60bn
- 66
- 62
- 98
- 92
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 12.76 | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | -24.32% | ||
| Dividend Yield (f) | 2.17% | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.04 | ||
| Price to Tang. Book | 1.09 | ||
| Price to Free Cashflow | 17.07 | ||
| Price to Sales | 1.01 | ||
| EV to EBITDA | 6.15 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 7.63% | ||
| Return on Equity | 11.38% | ||
| Operating Margin | 9.02% | ||
Financial Summary
| Year End 31st Mar | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | ¥m | 46,706 | 52,542 | 55,181 | 56,607 | 60,461 | 63,285 | 64,651 | 4.32% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | -27.33 | -29.38 | +119.75 | +25.95 | +25.45 | +50.77 | -24.32 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
ASKA Pharmaceutical Holdings Co Ltd is a Japan-based company mainly engaged in the pharmaceutical business. The Company mainly operates in two business segments. The Pharmaceutical segment is mainly engaged in the manufacture, purchase and sale of pharmaceutical products. The Others segment is involved in the manufacture of veterinary drugs, the provision of clinical testing services, the outsourcing of testing services, the purchase and sale of medical equipment, as well as the sale of health foods.
Directors
- Last Annual
- March 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- April 1st, 2021
- Public Since
- April 1st, 2021
- No. of Shareholders
- 7,462
- No. of Employees
- 747
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- Tokyo Stock Exchange
- Shares in Issue
- 28,329,242
- Address
- 2-5-1, Shibaura, MINATO-KU, 108-8532
- Web
- https://www.aska-pharma-hd.co.jp/
- Phone
- +81 354848845
- Auditors
- Seiyo Audit Corporation
Upcoming Events for 4886
Similar to 4886
Astellas Pharma
Tokyo Stock Exchange
Astena Holdings Co
Tokyo Stock Exchange
CanBas Co
Tokyo Stock Exchange
CellSeed
Tokyo Stock Exchange
Chugai Pharmaceutical Co
Tokyo Stock Exchange
FAQ
What is the ASKA Pharmaceutical Holdings Co share price?
As of Today at 19:03 UTC, shares in ASKA Pharmaceutical Holdings Co are trading at ¥2,207. This share price information is delayed by 15 minutes.
How has the ASKA Pharmaceutical Holdings Co share price performed this year?
Shares in ASKA Pharmaceutical Holdings Co last closed at ¥2,207 and the price had moved by +82.25% over the past 365 days. In terms of relative price strength the ASKA Pharmaceutical Holdings Co share price has outperformed the Nikkei 225 Index by +37.15% over the past year.
What are the analyst and broker recommendations for ASKA Pharmaceutical Holdings Co?
The overall consensus recommendation for ASKA Pharmaceutical Holdings Co is Strong Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the ASKA Pharmaceutical Holdings Co dividend yield?
The ASKA Pharmaceutical Holdings Co dividend yield is 1.27% based on the trailing twelve month period.
Does ASKA Pharmaceutical Holdings Co pay a dividend?
Last year, ASKA Pharmaceutical Holdings Co paid a total dividend of ¥28, and it currently has a trailing dividend yield of 1.27%. We do not have any data on when ASKA Pharmaceutical Holdings Co is to next pay dividends.
When does ASKA Pharmaceutical Holdings Co next pay dividends?
We do not have data on when ASKA Pharmaceutical Holdings Co is to next pay dividends. The historic dividend yield on ASKA Pharmaceutical Holdings Co shares is currently 1.27%.
How do I buy ASKA Pharmaceutical Holdings Co shares?
To buy shares in ASKA Pharmaceutical Holdings Co you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of ASKA Pharmaceutical Holdings Co?
As of the previous close price of ¥2,207, shares in ASKA Pharmaceutical Holdings Co had a market capitalisation of ¥63bn.
Where are ASKA Pharmaceutical Holdings Co shares listed?
Here are the trading details for ASKA Pharmaceutical Holdings Co:
- Country of listing: Japan
- Exchange: TYO
- Ticker Symbol: 4886
What kind of share is ASKA Pharmaceutical Holdings Co?
Based on an overall assessment of its quality, value and momentum ASKA Pharmaceutical Holdings Co is currently classified as a Super Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a ASKA Pharmaceutical Holdings Co share price forecast for 2024?
The analyst consensus target price for shares in ASKA Pharmaceutical Holdings Co is ¥2,450. That is 11.01% above the last closing price of ¥2,207.
Analysts covering ASKA Pharmaceutical Holdings Co currently have a consensus Earnings Per Share (EPS) forecast of ¥228 for the next financial year.
What is the trend in the ASKA Pharmaceutical Holdings Co share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like ASKA Pharmaceutical Holdings Co. Over the past six months, its share price has outperformed the Nikkei 225 Index by +4.64%.
As of the last closing price of ¥2,207, shares in ASKA Pharmaceutical Holdings Co were trading +22.28% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the ASKA Pharmaceutical Holdings Co PE Ratio?
The ASKA Pharmaceutical Holdings Co PE ratio based on its reported earnings over the past 12 months is 12.76. The shares last closed at ¥2,207.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of ASKA Pharmaceutical Holdings Co?
We do not have data on ASKA Pharmaceutical Holdings Co's directors